CAR T-Cell Therapy for Large B-Cell Lymphoma - Who, When, and How?
作者信息
Roschewski Mark, Longo Dan L, Wilson Wyndham H
机构信息
From the Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD (M.R., W.H.W.).
出版信息
N Engl J Med. 2022 Feb 17;386(7):692-696. doi: 10.1056/NEJMe2118899. Epub 2021 Dec 14.
Abstract
摘要
相似文献
1
CAR T-Cell Therapy for Large B-Cell Lymphoma - Who, When, and How?
N Engl J Med. 2022 Feb 17;386(7):692-696. doi: 10.1056/NEJMe2118899. Epub 2021 Dec 14.
2
Can we truly define 'Fitness' for CAR-T therapy in large B cell lymphoma patients?
Chin Clin Oncol. 2024 Feb;13(1):15. doi: 10.21037/cco-23-78. Epub 2023 Oct 24.
3
NICE approves routine NHS use of CAR-T for diffuse large B-cell lymphoma.
Lancet Oncol. 2023 Mar;24(3):208. doi: 10.1016/S1470-2045(23)00054-2. Epub 2023 Feb 2.
4
Anti-CD19 Chimeric Antigen Receptor T Cell Therapies: Harnessing the Power of the Immune System to Fight Diffuse Large B Cell Lymphoma.
Curr Hematol Malig Rep. 2018 Dec;13(6):534-542. doi: 10.1007/s11899-018-0482-6.
5
Clinical predictors of chimeric antigen receptor T-cell therapy neurotoxicity: a single-center study.
Immunotherapy. 2021 Oct;13(15):1261-1269. doi: 10.2217/imt-2021-0084. Epub 2021 Sep 24.
6
Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma: Practical Implications for the Community Oncologist.
Oncologist. 2020 Jan;25(1):e138-e146. doi: 10.1634/theoncologist.2019-0395. Epub 2019 Oct 4.
7
Relapsed or refractory large B-cell lymphoma after chimeric antigen receptor T-cell therapy: Current challenges and therapeutic options.
Br J Haematol. 2023 Apr;201(1):15-24. doi: 10.1111/bjh.18656. Epub 2023 Jan 29.
8
Efficacy and safety of zanubrutinib combined with chimeric antigen receptor T-cell therapy targeting CD19 in refractory or relapsed diffuse large B cell lymphoma: A retrospective analysis.
Cancer Treat Res Commun. 2025;43:100902. doi: 10.1016/j.ctarc.2025.100902. Epub 2025 Mar 29.
9
CD19 CAR-T cell therapy for relapsed or refractory diffuse large B cell lymphoma: Why does it fail?
Semin Hematol. 2023 Nov;60(5):329-337. doi: 10.1053/j.seminhematol.2023.11.007. Epub 2023 Dec 5.
10
Indicators describing the tumor lesion aggregation and dissemination and their impact on the prognosis of patients with diffuse large B cell lymphoma receiving chimeric antigen receptor T cell therapy.
Cancer Med. 2024 Mar;13(6):e6991. doi: 10.1002/cam4.6991.
引用本文的文献
1
CAR-T cell therapy in older adults with relapsed/refractory LBCL: benefits and challenges.
J Immunother Cancer. 2025 Jun 5;13(6):e009793. doi: 10.1136/jitc-2024-009793.
2
The Improving Outcomes in Relapsed-Refractory Diffuse Large B Cell Lymphoma: The Role of CAR T-Cell Therapy.
Curr Treat Options Oncol. 2025 Apr 28. doi: 10.1007/s11864-025-01305-9.
3
First-Line Combination of R-CHOP with the PDE4 Inhibitor Roflumilast for High-Risk DLBCL.
Cancers (Basel). 2024 Nov 18;16(22):3857. doi: 10.3390/cancers16223857.
4
Sequencing of therapy for patients with diffuse large B-cell lymphoma in the era of novel drugs.
Br J Haematol. 2024 Dec;205(6):2163-2174. doi: 10.1111/bjh.19860. Epub 2024 Oct 28.
5
A Case of Gastrointestinal Coccidiomycosis With Bowel Perforation Secondary to Relapsing DLBCL.
J Community Hosp Intern Med Perspect. 2024 Jul 2;14(4):89-92. doi: 10.55729/2000-9666.1376. eCollection 2024.
6
Increased CCL2/CCR2 axis promotes tumor progression by increasing M2 macrophages in MYC/BCL2 double-expressor DLBCL.
Blood Adv. 2024 Nov 26;8(22):5773-5788. doi: 10.1182/bloodadvances.2024013699.
7
CAR-NK Cell Therapy: A Transformative Approach to Overcoming Oncological Challenges.
Biomolecules. 2024 Aug 20;14(8):1035. doi: 10.3390/biom14081035.
8
The Immune Resistance Signature of Acute Myeloid Leukemia and Current Immunotherapy Strategies.
Cancers (Basel). 2024 Jul 23;16(15):2615. doi: 10.3390/cancers16152615.
9
Optimization of In Vitro Th17 Polarization for Adoptive Cell Therapy in Chronic Lymphocytic Leukemia.
Int J Mol Sci. 2024 Jun 7;25(12):6324. doi: 10.3390/ijms25126324.
10
Medicare Utilization and Cost Trends for CAR T Cell Therapies Across Settings of Care in the Treatment of Diffuse Large B-Cell Lymphoma.
Adv Ther. 2024 Aug;41(8):3232-3246. doi: 10.1007/s12325-024-02917-7. Epub 2024 Jun 25.
本文引用的文献
1
Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study.
Lancet Oncol. 2021 Oct;22(10):1403-1415. doi: 10.1016/S1470-2045(21)00375-2. Epub 2021 Sep 10.
2
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
Lancet. 2020 Sep 19;396(10254):839-852. doi: 10.1016/S0140-6736(20)31366-0. Epub 2020 Sep 1.
3
Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma.
Blood Adv. 2020 Jul 14;4(13):2871-2883. doi: 10.1182/bloodadvances.2020001837.
4
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.
Lancet Oncol. 2019 Jan;20(1):31-42. doi: 10.1016/S1470-2045(18)30864-7. Epub 2018 Dec 2.
5
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
N Engl J Med. 2019 Jan 3;380(1):45-56. doi: 10.1056/NEJMoa1804980. Epub 2018 Dec 1.
6
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.
N Engl J Med. 2018 Apr 12;378(15):1396-1407. doi: 10.1056/NEJMoa1801445.
7
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.
N Engl J Med. 2017 Dec 28;377(26):2531-2544. doi: 10.1056/NEJMoa1707447. Epub 2017 Dec 10.
8
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
J Clin Oncol. 2010 Sep 20;28(27):4184-90. doi: 10.1200/JCO.2010.28.1618. Epub 2010 Jul 26.
Zotero 插件